Cargando…
Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
Immune checkpoint inhibitors represent revolutionary anti-cancer agents, being rapidly approved in different malignancies and settings. Gastrointestinal (GI) cancers represent a wide variety of tumors with specific characteristics and different responses to various therapeutic alternatives; while so...
Autores principales: | Kourie, Hampig Raphael, Tabchi, Samer, Ghosn, Marwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423038/ https://www.ncbi.nlm.nih.gov/pubmed/28533658 http://dx.doi.org/10.3748/wjg.v23.i17.3017 |
Ejemplares similares
-
The future of cancer research after COVID-19 pandemic: recession?
por: Kourie, Hampig Raphael, et al.
Publicado: (2020) -
Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence
por: Moujaess, Elissar, et al.
Publicado: (2020) -
Immunotherapies in sarcoma: Updates and future perspectives
por: Ghosn, Marwan, et al.
Publicado: (2017) -
Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing?
por: Moujaess, Elissar, et al.
Publicado: (2020) -
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
por: Ghosn, Marwan, et al.
Publicado: (2016)